Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoDa Therapeutics Inc.

http://codathx.com/

Latest From CoDa Therapeutics Inc.

Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B

Private Company Edition: Morphic raises $80m to take its first two integrin inhibitors into the clinic for fibrosis and inflammatory bowel disease. Also, Hillhouse has a new $10.6bn private equity fund for health care and other investments, and Atreca closes a $125m Series C.

Financing Business Strategies

Regado Snags $51M From Venture Funding Led By Rusnano

New Jersey biotech Regado Biosciences raised $51 million in a Series E offering led by Russian investment group Rusnano. The money will be used to initiate a Phase III trial of its anticoagulant REG1.

BioPharmaceutical Business Strategies

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain

AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
UsernamePublicRestriction

Register